Compare GSK plc (GSK) vs Tempus AI (TEM) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Tempus AI (TEM) trades at $53.69, down 8.39% over 24 hours, with a neutral technical signal despite bullish moving averages. The company shows strong revenue growth ($1.27B in 2025) and consistent earnings beats, but remains unprofitable with negative net income margins (-22.2%). Recent news highlights AI deployment in healthcare systems and FDA clearances, supporting its data-driven healthcare platform.

The outlook balances high-growth potential in AI healthcare data against persistent profitability challenges. Analyst consensus is bullish with a $68.50 price target, but investors face risks from ongoing cash burn, competitive pressures, and execution hurdles as the company scales its platform toward sustainable margins.